New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients who had Histologic Inflammation on Baseline Biopsy – QNT Press Release

[ad_1]

DURHAM, NC, May 22, 2022 /PRNewswire/ — New data shows that more than a third (36.6%) of ulcerative colitis (UC) patients who have previously responded to advanced therapies experienced a loss of remission (LOR) in their symptom control, often within a year. The analysis from Target RWE’s TARGET-IBD large, longitudinal cohort, Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis, [Su1537] was presented today by Benjamin ClickMD, Associate Professor of Medicine, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, at Digestive Disease Week in San Diego.